Transcatheter Heart Valve Replacement (TAVR) Market Growth Accelerating with Rising Volumes of TAVI Procedures. Self–expandable transcatheter aortic valves are expected to give high growth at a CAGR of 16.0% between 2023 and 2033. Severe aortic valve stenosis by indication segment is predicted to expand rapidly with a CAGR of 15.1% between 2023 and 2033
As per Future Market Insights’ latest industry analysis, the valuation for the global Transcatheter Heart Valve Replacement (TAVR) Market was around US$ 5.7 Billion in 2022 and is projected to exhibit a CAGR of 14.8% over the forecast period, with an estimated valuation of US$ 25.4 Billion in 2033.
The rising prevalence of various cardiovascular diseases like valvular heart diseases such as aortic stenosis is one of the major causes of the increased volume of TAVI procedures on a global level, depending on the severity of the diseases. There are various benefits offered by minimally invasive procedures due to which there is a surge in demand for minimally invasive surgeries.
Since the TAVI is a minimally invasive procedure, which involves the implantation of a new valve inside the patient’s heart in order to remove the old or damaged valve, therefore this surging demand for minimally invasive procedures can have a positive impact on the growth of the TAVR market.
Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-537
TAVR is a very crucial procedure because it helps in rectifying the sensitive function of the heart in reference to the valves. It is very important that regulatory bodies like FDA should check for the safety and efficacy of TAVR-related products. In the last decade there have been multiple FDA approvals when it comes to TAVI procedures, this paves the way for the growth of the TAVR market.
Key Takeaways from Market Study
- Balloon–expandable transcatheter aortic valves are the leading segment as product, and hold approximately 52.5% market value share in 2022, owing to lower rates of complications post-surgery.
- Severe aortic valve stenosis segment is set to lead in terms of indication of transcatheter heart valve replacement (TAVR) with a projected market value share of around 79.0% by 2033, owing to the rising prevalence of aortic stenosis.
- By end user, hospitals held a share of around 53.6% in 2022; however, independent cardiac catheterization labs are expected to grow at a CAGR of 17.5% during the forecasted years.
- North America held a value share of around 53.3% in 2022, owing to the highest number of TAVR procedures conducted in the region.
Ask An Analyst: https://www.futuremarketinsights.com/ask-question/rep-gb-537
“In light of the increasing demand for TAVR procedures over SAVR (Surgical Aortic Valve Replacement) and the increasing prevalence of cardiac diseases, along with the growing demand for minimally invasive procedures, the market for TAVR is predicted to expand globally,” says an analyst of Future Market Insights.
Market Competition
The capacity of healthcare systems and intensive care units (ICUs) has been substantially challenged by the coronavirus disease 2019 (COVID-19) pandemic, resulting in the suspension of the majority of elective treatments, including transcatheter aortic valve replacement (TAVR).
The market for transcatheter heart valve replacement (TAVR) represents a consolidated market. The market players are focused on developing and launching technologically improved valves in order to improve the efficiency and durability of the value and minimize post-operative complications.
- On 12 September 2022, Edwards Lifesciences launched the Sapien 3 Ultra Resilia Valve, after getting FDA approval, which will be the first dry storage transcatheter heart valve available in the United States.
- The U.S. FDA approved the PorticoTM with FlexNavTM transcatheter aortic valve replacement (TAVR) system from Abbott on September 20, 2021, for the treatment of patients with symptomatic, severe aortic stenosis. The business increased the scope of its structural cardiac solutions portfolio with this most recent TAVR development.
Request Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-537
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the transcatheter heart valve replacement (TAVR) market in its latest study, presenting a historical demand assessment of 2016–2022 and projections for 2023–2033. The global transcatheter heart valve replacement (TAVR) market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The research study is based on the product (self–expandable transcatheter aortic valves, balloon-expandable transcatheter aortic valves, and mechanically expanded transcatheter aortic valves), by indication (severe aortic valve stenosis, valve-in-valve procedures {failed bioprosthesis}, and aortic regurgitation), by end user (hospitals, independent cardiac catheterization labs, and ambulatory surgical centres), across seven key regions of the world.
About Healthcare Division at Future Market Insights
Future Market Insights facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage here.
Key Companies Profiled
- Abbott
- Edwards Lifesciences Corporation
- Medtronic
- Boston Scientific Corporation
- JenaValve Technology, Inc
- Meril Life Sciences
- Sahajanand Medical Technologies Limited
- MicroPort Scientific Corporation
- Venus Medtech (Hangzhou) Inc.
- Suzhou Jiecheng Medical Technology Co. Ltd.
- Peijia Medical Limited.
- Blue Sail Medical Co., Ltd.
Key Market Segments Covered in the Transcatheter Heart Valve Replacement Industry Research
Product:
- Self – Expandable Transcatheter Aortic Valves
- Balloon-Expandable Transcatheter Aortic Valves
- Mechanically Expanded Transcatheter Aortic Valves
Indication:
- Severe Aortic Valve Stenosis
- Valve-in-Valve Procedures (Failed Bioprosthesis)
- Aortic Regurgitation
End User:
- Hospitals
- Independent Cardiac Catheterization Labs
- Ambulatory Surgical Centres
Get Full Access: https://www.futuremarketinsights.com/reports/transcatheter-heart-valve-replacement-tavi-market
Table of Content
1. Executive Summary | Transcatheter Heart Valve Replacement (TAVR) Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
Request a Complete TOC of this Report@ https://www.futuremarketinsights.com/toc/rep-gb-537
Explore FMI’s related ongoing Coverage on Healthcare Market Insights Domain
Blood Collection Devices Market Size: The blood collection devices market is expected to register a CAGR of 6.5% during the forecast period. In 2023, the market valuation is expected to be at US$ 7.7 billion. By 2033, the figures are expected to cross US$ 14.4 billion.
Enteral Feeding Devices Market Growth: The enteral feeding devices market is likely to expand its roots at an average CAGR of 4.0% during the forecast period. The market is anticipated to hold a share of US$ 2.8 billion in 2023 while it is anticipated to cross a value of US$ 4.1 billion by 2033.
Mechanical Ventilator Market Demand: Newly-released Mechanical Ventilator industry analysis report by Future Market Insights shows that global sales of Mechanical Ventilator in 2022 were held at US$ 5.7 Billion. With a CAGR of 5.7% from 2023 to 2033, the market is projected to reach a valuation of US$ 10.5 Billion by 2033.
Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market Share: The global atypical hemolytic uremic syndrome (ahus) treatment market is expected to garner a market value of US$ 1431 Million in 2023 and is expected to accumulate a market value of US$ 2308.84 Million by registering a CAGR of 4.9% in the forecast period 2023 to 2033.
Salivary Gland Infection Treatment Market Growth: The global salivary gland infection treatment market is expected to garner a market value of US$ 5054.79 Million in 2023 and is expected to accumulate a market value of US$ 12,300 Million by registering a CAGR of 9.3% in the forecast period 2023 to 2033.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
